216 related articles for article (PubMed ID: 38163150)
1. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
Wang H; Cai H; Li L
Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
[TBL] [Abstract][Full Text] [Related]
2. N6-methyladenosine methylation-related genes
Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
4. Systematic Analyses of the Role of the Reader Protein of
Shao XY; Dong J; Zhang H; Wu YS; Zheng L
Front Mol Biosci; 2020; 7():577460. PubMed ID: 33344502
[TBL] [Abstract][Full Text] [Related]
5. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
6. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
[No Abstract] [Full Text] [Related]
8. YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.
Chen G; Ren D; Wang Y; Wang H; Zhang J; Yang S
J Mol Histol; 2023 Aug; 54(4):365-377. PubMed ID: 37357252
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
Liu T; Wang Y; Li Z; Sun L; Yang K; Chen J; Han X; Qi L; Zhou X; Wang P
Heliyon; 2023 Nov; 9(11):e21285. PubMed ID: 38027812
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
11. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
12. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma.
Wang Y; Li N; Tian D; Zhou CW; Wang YH; Yang C; Zeng MS
Cancer Manag Res; 2021; 13():6451-6471. PubMed ID: 34429653
[TBL] [Abstract][Full Text] [Related]
13. Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients.
Zheng X; Zhang Y; Wang Y; He Z; Zhang Q; Ren D; Yan X; Yuan X
Front Surg; 2023; 10():1052100. PubMed ID: 36936652
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
[No Abstract] [Full Text] [Related]
16. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.
Yu H; Wang C; Ke S; Bai M; Xu Y; Lu S; Feng Z; Qian B; Xu Y; Zhou M; Li Z; Yin B; Li X; Hua Y; Zhou Y; Pan S; Fu Y; Ma Y
Front Immunol; 2022; 13():892750. PubMed ID: 35812416
[TBL] [Abstract][Full Text] [Related]
17. Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.
Wen F; Meng F; Li X; Li Q; Liu J; Zhang R; Zhao Y; Zhang Y; Wang X; Ju S; Cui Y; Lu Z
Front Immunol; 2023; 14():1086342. PubMed ID: 36936971
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
19. N6-methyladenosine associated prognostic model in hepatocellular carcinoma.
Huang H; Bai Y; Lu X; Xu Y; Zhao H; Sang X
Ann Transl Med; 2020 May; 8(10):633. PubMed ID: 32566570
[TBL] [Abstract][Full Text] [Related]
20. The Effect of m6A Methylation Regulatory Factors on the Malignant Progression and Clinical Prognosis of Hepatocellular Carcinoma.
Zhao Z; Yang L; Fang S; Zheng L; Wu F; Chen W; Song J; Chen M; Ji J
Front Oncol; 2020; 10():1435. PubMed ID: 32974160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
